As early as 3 weeks after AAV8-TBG-Cebpa dosing in HFCFD-fed C57BL/6N mice, hepatic Cebpa mRNA was increased, while hepatic Spp1 mRNA and serum OPN were decreased, in the absence of obvious phenotypic changes of biochemical endpoints and liver fibrosis (Supplemental Figure 10, I–P), supporting the view that CEBPA overexpression–mediated Spp1 downregulation could be an early causal factor for decreasing liver fibrosis. The gene discussed is CEBPA; the disease is Hepatic fibrosis.